$-0.07
(Market cap
$11 Mln
Recently Viewed
Clear AllMarket cap
$11 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
19.4
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-3.2 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
0.2
Debt to Equity
-1.1
Book Value
$--
EPS
$-0
Face value
--
Shares outstanding
8,766,516
CFO
$-136.72 Mln
EBITDA
$-147.81 Mln
Net Profit
$-160.82 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Biomx Inc (PHGE)
| -39.6 | -75.6 | -71.8 | -89.9 | -72.5 | -75.4 | -- |
|
BSE Sensex
| -9.5 | 5.5 | -6.0 | -4.3 | 8.7 | 9.9 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|---|
|
Biomx Inc (PHGE)
| -86.5 | -73.6 | 49.7 | -88.3 | -74.9 | -34.1 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Biomx Inc (PHGE)
|
1.1 | 10.5 | 0.0 | -36.2 | -- | -316.9 | -- | 19.4 |
| 73.9 | 10,349.8 | 1,091.0 | 202.3 | 31.6 | 31.3 | 46.2 | 18.2 | |
| 65.3 | 8,115.2 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 44.9 | 11,415.1 | 2,320.1 | 782.6 | 39.0 | 35.5 | 16.2 | 5.3 | |
| 88.9 | 11,662.4 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 65.4 | 7,743.5 | 1,396.6 | 316.9 | 59.8 | 153.6 | 26 | 161.6 | |
| 512.4 | 11,754.2 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 19.5 | |
| 410.5 | 11,724.9 | 2,678.3 | 460.4 | 21.1 | 103.2 | 25.9 | 19.6 | |
| 104.5 | 8,215.5 | 0.0 | -425.4 | -- | -36.7 | -- | 6.6 | |
| 344.8 | 9,603.5 | 0.0 | -303.3 | -- | -45.8 | -- | 10.9 |
BiomX Inc., a clinical-stage biopharmaceutical company, develops phage-based therapies using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company's phage-based... therapies include fixed cocktail therapy, which involves developing a single product containing a fixed number of selected phages to cover a range of bacterial strains; and personalized therapy, which involves developing a large library of phages from which single optimal phages are personally matched to treat specific patients. It develops BX011, a fixed multi-phage cocktail, which is in Phase 2a trial for the treatment of diabetic foot infections; and BX211, a phage therapy, which is in Phase 2 trial for the treatment of diabetic foot osteomyelitis. BiomX Inc. was founded in 2015 and is based in Dover, Delaware. Read more
CEO & Director
Mr. Jonathan Eitan Solomon MBA
Scientific Founder
Prof. Rotem Sorek Ph.D.
Headquarters
Dover, DE
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Biomx Inc (PHGE) is $1.13 (NYSE) as of 24-Apr-2026 16:10 EDT. Biomx Inc (PHGE) has given a return of -72.5% in the last 3 years.
Since, TTM earnings of Biomx Inc (PHGE) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-84.26
|
-2,342.58
|
|
2024
|
-0.39
|
0.29
|
|
2023
|
-0.05
|
0.42
|
|
2022
|
-0.01
|
0.01
|
|
2021
|
-0.07
|
0.05
|
The 52-week high and low of Biomx Inc (PHGE) are Rs 105.12 and Rs 1.06 as of 26-Apr-2026.
Biomx Inc (PHGE) has a market capitalisation of $ 11 Mln as on 24-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Biomx Inc (PHGE), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.